Cited by 210HIV-related health complications and treatmentsDiabetes, Cardiovascular Risks, and LipoproteinsHIV/AIDS Research and Interventions

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV*

Open access
Lundgren, JD, Battegay, M, Behrens, G, De Wit, S, Guaraldi, G, Katlama, C, Martinez, E, Nair, D +5 more·2008·HIV Medicine

Abstract

Background: Metabolic diseases are frequently observed in HIV‐infected persons and, as the risk of contracting these diseases is age‐related, their prevalence will increase in the future as a consequence of the benefits of antiretroviral therapy (ART). Summary of guidelines: All HIV‐infected persons should be screened at regular intervals for a history of metabolic disease, dyslipidaemia, diabetes mellitus, hypertension and alteration of body composition; cardiovascular risk and renal function should also be assessed. Efforts to prevent cardiovascular disease will vary in intensity depending on an individual's absolute risk of ischaemic heart disease and should be comprehensive in nature. Lifestyle interventions should focus on counselling to stop smoking, modify diet and take regular exercise. A healthy diet, exercise and maintaining normal body weight tend to reduce dyslipidaemia; if not effective, a change of ART should be considered, followed by use of lipid‐lowering medication in high‐risk patients. A pre‐emptive switch from thymidine analogues is recommended to reduce the risk of development or progression of lipoatrophy. Intra‐abdominal fat accumulation is best managed by exercise and diet. Prevention and management of type 2 diabetes mellitus and hypertension follow guidelines used in the general population. When using medical interventions to prevent and/or treat metabolic disease(s), impairment of the efficacy of ART should be avoided by considering the possibility of pharmacokinetic interactions and compromised adherence. Specialists in HIV and specialists in metabolic diseases should consult each other, in particular in difficult‐to‐treat cases. Conclusion: Multiple and relatively simple approaches exist to prevent metabolic diseases in HIV‐infected persons; priority should be given to patients at high risk of contracting these diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1468-1293.2007.00534.x

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • According to the European AIDS Clinical Society, simvastatin is contraindicated in patients receiving ritonavir-boosted protease inhibitor-based antiretroviral treatment.

    “according to the European AIDS Clinical Society simvastatin is contraindicated in patients receiving ritonavir-boosted protease inhibitorbased antiretroviral treatment 214”

    From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [214]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 18 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Ryden L, Standl E, Bartnik M et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J 2007; 28: 88-136.
  2. Cifkova R, Erdine S, Fagard R et al. ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21: 1779-1786.

Cited by

Sorted by citations

Authors
Lundgren, J., Battegay, M., Behrens, G., De Wit, S., Guaraldi, G., Katlama, C., Martinez, E., Nair, D., Powderly, W., Reiss, P., Sutinen, J., Vigano, A., & the EACS Executive Committee
Affiliations
  • University Hospital of Basel (CH)
  • Medizinische Hochschule Hannover (DE)
  • University of Modena and Reggio Emilia (IT)
  • Pitié-Salpêtrière Hospital (FR)
  • The Royal Free Hospital (GB)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Helsinki University Hospital (FI)
Venue
HIV Medicine
Publisher
Wiley
Published
2008-01-31
Volume
9
Issue
2
Pages
72-81
ISSN
  • 1464-2662 (ISSN-L)
  • 1468-1293
OpenAlex
W2032218832
Cited by
210
References
18
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 5 · 2020: 5 · 2019: 9 · 2018: 5 · 2017: 8 · 2016: 14 · 2015: 14 · 2014: 13 · 2013: 22 · 2012: 19
FWCI
30.19
Type
journal article
Language
en
Open access
Locations
  • HIV Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Emergency Medicine › HIV-related health complications and treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Keywords
dyslipidemia, type 2 diabetes, hypertension, lipoatrophy, intra-abdominal fat, cardiovascular risk, antiretroviral therapy, lipid-lowering therapy, lifestyle intervention, body composition, renal function, pharmacokinetic interactions, medication adherence, screening
MeSH terms
Cardiovascular Diseases, Drug Interactions, Humans, Life Style, Metabolic Diseases, HIV Infections, Polypharmacy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review